Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita
Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted it a licence following an FDA rejection in August.